These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 30037690)

  • 1. Neuromelanin-sensitive MRI of the substantia nigra: An imaging biomarker to differentiate essential tremor from tremor-dominant Parkinson's disease.
    Wang J; Huang Z; Li Y; Ye F; Wang C; Zhang Y; Cheng X; Fei G; Liu K; Zeng M; Zhong C; Jin L
    Parkinsonism Relat Disord; 2019 Jan; 58():3-8. PubMed ID: 30037690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
    Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
    Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease.
    Prasad S; Stezin A; Lenka A; George L; Saini J; Yadav R; Pal PK
    Eur J Neurol; 2018 Apr; 25(4):680-686. PubMed ID: 29341412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Azevedo P; Ferreira J; Abreu D; Gonçalves N; Nunes RG; Campos J; Ferreira JJ
    Mov Disord; 2015 Jun; 30(7):953-9. PubMed ID: 25758364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive markers for Parkinson's disease using deep neural nets on neuromelanin sensitive MRI.
    Shinde S; Prasad S; Saboo Y; Kaushick R; Saini J; Pal PK; Ingalhalikar M
    Neuroimage Clin; 2019; 22():101748. PubMed ID: 30870733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtypes evaluation of motor dysfunction in Parkinson's disease using neuromelanin-sensitive magnetic resonance imaging.
    Xiang Y; Gong T; Wu J; Li J; Chen Y; Wang Y; Li S; Cong L; Lin Y; Han Y; Yin L; Wang G; Du Y
    Neurosci Lett; 2017 Jan; 638():145-150. PubMed ID: 27993708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
    Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NigraNet: An automatic framework to assess nigral neuromelanin content in early Parkinson's disease using convolutional neural network.
    Gaurav R; Valabrègue R; Yahia-Chérif L; Mangone G; Narayanan S; Arnulf I; Vidailhet M; Corvol JC; Lehéricy S
    Neuroimage Clin; 2022; 36():103250. PubMed ID: 36451356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease.
    Castellanos G; Fernández-Seara MA; Lorenzo-Betancor O; Ortega-Cubero S; Puigvert M; Uranga J; Vidorreta M; Irigoyen J; Lorenzo E; Muñoz-Barrutia A; Ortiz-de-Solorzano C; Pastor P; Pastor MA
    Mov Disord; 2015 Jun; 30(7):945-52. PubMed ID: 25772492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motor asymmetry and neuromelanin imaging: Concordance in Parkinson's disease.
    Prasad S; Saini J; Yadav R; Pal PK
    Parkinsonism Relat Disord; 2018 Aug; 53():28-32. PubMed ID: 29709506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnostic value of SNpc using NM-MRI in Parkinson's disease: meta-analysis.
    Wang X; Zhang Y; Zhu C; Li G; Kang J; Chen F; Yang L
    Neurol Sci; 2019 Dec; 40(12):2479-2489. PubMed ID: 31392640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microstructural abnormalities of substantia nigra in Parkinson's disease: A neuromelanin sensitive MRI atlas based study.
    Safai A; Prasad S; Chougule T; Saini J; Pal PK; Ingalhalikar M
    Hum Brain Mapp; 2020 Apr; 41(5):1323-1333. PubMed ID: 31778276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substantia nigra neuromelanin magnetic resonance imaging in patients with different subtypes of Parkinson disease.
    Wang L; Yan Y; Zhang L; Liu Y; Luo R; Chang Y
    J Neural Transm (Vienna); 2021 Feb; 128(2):171-179. PubMed ID: 33559725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.
    Reimão S; Pita Lobo P; Neutel D; Correia Guedes L; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    Eur J Neurol; 2015 Mar; 22(3):540-6. PubMed ID: 25534480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
    Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
    J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
    Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
    Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease.
    Ogisu K; Kudo K; Sasaki M; Sakushima K; Yabe I; Sasaki H; Terae S; Nakanishi M; Shirato H
    Neuroradiology; 2013 Jun; 55(6):719-24. PubMed ID: 23525598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging.
    Ohtsuka C; Sasaki M; Konno K; Koide M; Kato K; Takahashi J; Takahashi S; Kudo K; Yamashita F; Terayama Y
    Neurosci Lett; 2013 Apr; 541():93-8. PubMed ID: 23428505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Study of MRI Biomarkers in the Substantia Nigra to Discriminate Idiopathic Parkinson Disease.
    Pyatigorskaya N; Magnin B; Mongin M; Yahia-Cherif L; Valabregue R; Arnaldi D; Ewenczyk C; Poupon C; Vidailhet M; Lehéricy S
    AJNR Am J Neuroradiol; 2018 Aug; 39(8):1460-1467. PubMed ID: 29954816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The utility of the combined use of
    Matsusue E; Fujihara Y; Tanaka K; Aozasa Y; Shimoda M; Nakayasu H; Nakamura K; Ogawa T
    Acta Radiol; 2019 Feb; 60(2):230-238. PubMed ID: 29804474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.